PTC Therapeutics, Inc. Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Sephience Launch: EU approval in June, FDA approval in July. U.S. launch planned within 2 weeks. European launch initiated in Germany, leveraging early access mechanisms. Agreed to purchase Censa Pharmaceuticals' annual global net sales payment obligation for ~$225 million upfront.
• DMD Franchise: Translarna revenue in Europe via Article 117 agreements, maintaining ~25% of prior European revenue.
• Vatiquinone and Translarna NDAs: Vatiquinone NDA under FDA review, late cycle meeting held in July with FDA still reviewing. Translarna NDA under active review with clinical site inspections completed.
• Huntington's Disease Program: PTC518 Phase II PIVOT-HD study positive, collaborating with Novartis to meet FDA in Q4 to discuss Phase III trial design and accelerated approval.
• Financial Position: Cash, cash equivalents, and marketable securities totaled $1.989 billion as of June 30, 2025, allowing support for commercial and R&D initiatives.

Segment Performance

• DMD Franchise: Translarna net product revenue in the quarter was $59 million, Emflaza net product revenue was $36 million. Evrysdi generated royalty revenue of $58 million for PTC.
• Sephience: EU approved in late June with broad labeling, FDA approved in late July for patients aged 1 month and above. U.S. revenue opportunity exceeds $1 billion. European revenue expected to maintain approximately 25% of prior levels for remainder of 2025.
• Other Products: Tegsedi and Waylivra in Latin America; Upstaza and KEBILIDI with new AADC patients treated.

Guidance

• Revenue: Full-year 2025 guidance remains $650 million to $800 million, including revenue from existing products and new product launches like Sephience.
• Sephience Impact: Anticipates significant revenue opportunity from Sephience, with U.S. revenue potential over $1 billion.

Risks

• Regulatory Uncertainties: Uncertainties around FDA reviews for vatiquinone, Translarna, and Huntington's disease program.
• European Market Dynamics: Variability in European countries' use of Article 117 for Translarna, affecting revenue.
• Competition and Reimbursement: Challenges in pricing, reimbursement, and competition in rare disease markets.

Question and Answer

Q: On Huntington's trial design and Translarna in Europe under Article 117 A: Matt Klein discussed engagement with FDA on Huntington's trial design and Translarna's European revenue expectations under Article 117.

Q: Sephience launch metrics and scripts A: Eric Pauwels mentioned metrics like prescriptions, patient start forms, and health care provider dynamics; scripts received in U.S. and Europe.

Q: Sephience sales guidance and PKU launch A: Matthew Klein and Pierre Gravier discussed sales guidance including Sephience revenue and PKU launch sequencing.

Q: Vatiquinone and BD opportunities A: Matthew Klein and Pierre Gravier talked about vatiquinone's potential launch and BD strategies focusing on complementary assets.